Abstract
As the most abundant component of the complement system, C3 and its proteolytic derivatives serve essential roles in the function of all three complement pathways. Central to this is a network of protein-protein interactions made possible by the sequential proteolysis and far-reaching structural changes that accompany C3 activation. Beginning with the crystal structures of C3, C3b, and C3c nearly twenty years ago, the physical transformations underlying C3 function that had long been suspected were finally revealed. In the years that followed, a compendium of crystallographic information on C3 derivatives bound to various enzymes, regulators, receptors, and inhibitors generated new levels of insight into the structure and function of the C3 molecule. This Review provides a concise classification, summary, and interpretation of the more than 50 unique crystal structure determinations for human C3. It also highlights other salient features of C3 structure that were made possible through solution-based methods, including Hydrogen/Deuterium Exchange and Small Angle X-ray Scattering. At this pivotal time when the first C3-targeted therapeutics begin to see use in the clinic, some perspectives are also offered on how this continually growing body of structural information might be leveraged for future development of next-generation C3 inhibitors.
Original language | English |
---|---|
Article number | 101627 |
Number of pages | 17 |
Journal | Seminars in Immunology |
Volume | 59 |
DOIs | |
Publication status | Published - Jan 2022 |
Bibliographical note
Funding Information:This research was supported by a grant R35GM140852 from the U.S. National Institutes of Health to B.V.G., by the R. Weaver and S. Weaver endowment to J.D.L, and by the NWO Spinoza prize from the Netherlands Organisation for Scientific Research (NWO) and funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 787241) to P.G.
Funding Information:
This research was supported by a grant R35GM140852 from the U.S. National Institutes of Health to B.V.G., by the R. Weaver and S. Weaver endowment to J.D.L, and by the NWO Spinoza prize from the Netherlands Organisation for Scientific Research (NWO) and funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 787241 ) to P.G.
Publisher Copyright:
© 2022 The Authors
Funding
This research was supported by a grant R35GM140852 from the U.S. National Institutes of Health to B.V.G., by the R. Weaver and S. Weaver endowment to J.D.L, and by the NWO Spinoza prize from the Netherlands Organisation for Scientific Research (NWO) and funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 787241) to P.G. This research was supported by a grant R35GM140852 from the U.S. National Institutes of Health to B.V.G., by the R. Weaver and S. Weaver endowment to J.D.L, and by the NWO Spinoza prize from the Netherlands Organisation for Scientific Research (NWO) and funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 787241 ) to P.G.
Keywords
- Alternative pathway
- C3
- Complement
- Convertase
- Inhibitor
- Structural biology